SK bioscience announced on the 31st that its consolidated revenue for the second quarter of this year was 161.9 billion won, a 504.5% increase compared to the same period last year.
The operating loss was 37.4 billion won, an increase from 19.9 billion won during the same period last year. The net loss was 16.8 billion won, with the deficit widening. The company noted that the operating loss continued due to clinical trials and research and development (R&D) of key pipelines (new drug candidates), as well as facility investments.
SK bioscience explained that IDT Biologika, a contract development and manufacturing organization (CDMO) it incorporated as a subsidiary last year, showed stable growth in the second quarter as in the first, with productivity improvements and additional orders.
The company said, "IDT has achieved over 100 billion won in revenue for three consecutive quarters since the acquisition, and will focus on expanding CDMO orders and securing new partners mainly among European and North American clients in the second half of the year."
The company announced that it is expanding exports of its self-developed flu vaccine "Skycellflu" to Southeast Asian countries such as Thailand and Malaysia, and is preparing to ship quantities to the Northern Hemisphere. Starting next month, domestic supplies for this year and next winter are expected to be provided in earnest.
The chickenpox vaccine "Skyvaricella" is expected to begin deliveries from mid-second quarter under a supply contract with the Pan American Health Organization (PAHO) signed through 2027, with substantial sales recognition anticipated starting in the third quarter.
The shingles vaccine "Skyzoster" is currently undergoing the approval process for expansion in local government supply while also aiming for entry into the Southeast Asian market. The distribution products from the French pharmaceutical corporations Sanofi, which started domestic supply this year, are also expected to significantly grow in performance, the company explained.
SK bioscience plans to continue its investment in R&D for future growth. It is also co-developing a 21-valent pneumococcal conjugate vaccine with Sanofi.